Manufacturing Roundup - 19 March 2019

Several firms are looking to expand their manufacturing capabilities through acquisitions and investments; however a number of companies are suffering setbacks. Biocon gets hit with six ‘Form 483’ observations across two sites in India, as Jubilant, Pfizer’s Hospira and Andapharm are slapped with FDA warning letters.